Head and neck squamous cell carcinoma in people living with HIV in France.
CONCLUSION: The prevalence of HNSCC is modest compared with other cancers in HIV-infected individuals. The prevalence of oropharynx carcinoma, a potentially HPV-related carcinoma, seems to increase over time. Even if tobacco may be an important contributor, the role of HPV in HIV-infected individuals presenting with HNSCC should be investigated. PMID: 29887186 [PubMed - as supplied by publisher]
Publication date: Available online 20 October 2018Source: Urology Case ReportsAuthor(s): Y. Ayari
Authors: Fisichella R, Benfatto S, Berretta S PMID: 30338830 [PubMed - in process]
CONCLUSION: Oropharynx cancer with significant p16 expression showed an increased overall survival and elevated T- and B-lymphocyte infiltration, which suggests a prognostic relevance of immune cell infiltration. PMID: 29493423 [PubMed - as supplied by publisher]
This article is a continuation of the “Do You Know Your Guidelines” series, initiated by the Education committee of the American Head and Neck Society. Treatment guidelines for advanced head and neck squamous cell carcinoma are reviewed here, including the critical roles of radiotherapy, chemotherapy, and the recent application of immunotherapy agents. We will be limiting this discussion to include cancers of the oral cavity, oropharynx, hypopharynx, and larynx. It should be noted that much of the article pertains to human papillomavirus (HPV)‐negative oropharyngeal cancer where applicable, as HPV‐positive ...
Conclusion: BM in HNSCC is mostly multiple, associated with extracranial metastasis and can occur in patients without locoregional relapse or residual disease and carries a dismal outcome.
BackgroundTreatment intensification for resected, high-risk, head and neck squamous cell carcinoma (HNSCC) is an area of active investigation with novel adjuvant regimens under study. In this trial, the epidermal growth-factor receptor (EGFR) pathway was targeted using the IgG2 monoclonal antibody panitumumab in combination with cisplatin chemoradiotherapy (CRT) in high-risk, resected HNSCC.Patients and methodsEligible patients included resected pathologic stage III or IVA squamous cell carcinoma of the oral cavity, larynx, hypopharynx, or human-papillomavirus (HPV)-negative oropharynx, without gross residual tumor, featur...
ConclusionsAs such, GAL and GALR1/2 methylation status may serve as an important site‐specific biomarker for prediction of clinical outcome in patients with HNSCC. This article is protected by copyright. All rights reserved
ConclusionThe findings confirm the association between smoking history and survival and the importance of clinical variables in evaluating smoking as a prognostic factor. Timing, intensity, and duration of cigarette use should be considered with other prognostic factors when considering risk stratification for treatment planning. © 2016 Wiley Periodicals, Inc. Head Neck, 2016
Conclusions The present data do not provide evidence for a role of genetic variations in EVER1 or EVER2 for HPV status of mucosal HNSCC or between HNSCC patients and controls.
CONCLUSION: This update confirms the results of the 2-year report. We failed to identify a positive effect resulting from AF with regards to LRC, OS and CSS. The addition of information on the HPV-associated p16 overexpression did not explain this lack of effect. PMID: 26427805 [PubMed - as supplied by publisher]
More News: Cancer | Cancer & Oncology | Carcinoma | France Health | Genital Warts | Head and Neck Cancer | HNSCC | Human Papillomavirus (HPV) | Hypopharyngeal Cancer | Infectious Diseases | Laryngeal Cancer | Oral Cancer | Oral Cavity Cancer | Oropharyngeal Cancer | Skin Cancer | Smokers | Squamous Cell Carcinoma | Study